Jabil completed the acquisition of Pharmaceutics International from Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience.

Jabil, an engineering, manufacturing, and supply chain solutions, completed the acquisition of Pharmaceutics International, a contract development and manufacturing organization (CDMO) specializing in early stage, clinical, commercial volume aseptic filling, lyophilization and oral solid dose manufacturing, from Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience, a group of investors. Financial terms were not disclosed. "As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly with a focus on quality and safety. Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain," Mike Mahaz, Jabil SVP, Global Business Units.